Advertiment
Responding to the interim decision by NICE not to recommend bevacizumab (Avastin) as a treatment for metastic colorectal cancer, Mike Hobday, Head of Policy at Macmillan Cancer Support, said:
‘We think this is devastating news for cancer patients with metastic colorectal cancer, especially as this drug could have a significant impact on peoples’ quality of life. Although a few extra weeks or months might not sound much to some people it can mean an awful lot to a family affected by cancer.
‘Again this reiterates just how important it is that the government’s cancer drug fund comes into place sooner rather than later. On behalf of people living with cancer, Macmillan will hold the government to their £200 million commitment in order to ensure people with rarer cancers have fair access to clinically effective drugs.’
Source:
Macmillan Cancer Support
Related Search
NICE cancer drugs macmillan,
Leave a Reply
Suggested Posts
Joint Clinical Practice Guidelines On Hepatocellular Carcinoma Management To Be Published By EASL-EORTC Respo di g to the i terim decisio by NICE ot to recomme d bevacizumab (Avasti ) as a treatme t for metastic colorectal ca cer, Mike Hobday, Head of Policy at Macmilla Ca cer Support, said: ‘We thi k this is devastati g ews for ca cer patie ts with metastic colorectal ca cer, especially as this drug could have a sig ifica t impact o peoples’ quality of [...]. Posted August 26th, 2010 | 1:15 pm
New Evidence Strengthens Link Between Opioids And Cancer Growth Respo di g to the i terim decisio by NICE ot to recomme d bevacizumab (Avasti ) as a treatme t for metastic colorectal ca cer, Mike Hobday, Head of Policy at Macmilla Ca cer Support, said: ‘We thi k this is devastati g ews for ca cer patie ts with metastic colorectal ca cer, especially as this drug could have a sig ifica t impact o peoples’ quality of [...]. Posted August 26th, 2010 | 1:15 pm
Two Cancer-Promoting Pathways Linked In Esophageal Cancer Respo di g to the i terim decisio by NICE ot to recomme d bevacizumab (Avasti ) as a treatme t for metastic colorectal ca cer, Mike Hobday, Head of Policy at Macmilla Ca cer Support, said: ‘We thi k this is devastati g ews for ca cer patie ts with metastic colorectal ca cer, especially as this drug could have a sig ifica t impact o peoples’ quality of [...]. Posted August 26th, 2010 | 1:15 pm
Using Molecular Analysis To Identify Specific Cancers Respo di g to the i terim decisio by NICE ot to recomme d bevacizumab (Avasti ) as a treatme t for metastic colorectal ca cer, Mike Hobday, Head of Policy at Macmilla Ca cer Support, said: ‘We thi k this is devastati g ews for ca cer patie ts with metastic colorectal ca cer, especially as this drug could have a sig ifica t impact o peoples’ quality of [...]. Posted August 26th, 2010 | 1:15 pm
Establishing National Standards For Cancer Survivorship Care Respo di g to the i terim decisio by NICE ot to recomme d bevacizumab (Avasti ) as a treatme t for metastic colorectal ca cer, Mike Hobday, Head of Policy at Macmilla Ca cer Support, said: ‘We thi k this is devastati g ews for ca cer patie ts with metastic colorectal ca cer, especially as this drug could have a sig ifica t impact o peoples’ quality of [...]. Posted August 26th, 2010 | 1:15 pm